Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-10-10

Opinion for Spdr S&P Biotech Etf (XBI-N)

Signal Price Bias Subject Owned
TOP PICK $87.630 OPTIMISTIC US EQUITIES Yes

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

Cameron Hurst
Chief Investment Officer, Equium Capital Management

No Comments.


You must be logged in to comment.